Why keeping only popular parts of ACA won’t work

While President-elect Donald Trump may be offering a compromise on the Affordable Care Act (ACA) by keeping its ban on insurers denying coverage based on preexisting conditions, it’s doomed to fail if insurers can charge sick people more.

That’s according to Jonathan Gruber, PhD, a health economist at the Massachusetts Institute of Technology who helped the craft the ACA. Writing in the New York Times, Gruber said the pre-ACA insurance market, the primary source of profit was denying coverage to sick individuals. If insurers are allowed to charge much higher prices to people with pre-existing conditions, the coverage requirement won’t help.

“The insurer could offer coverage, but say that any breast-cancer survivor had to pay, say, five times more than everyone else. Both would be perfectly legal if the Affordable Care Act was repealed and replaced under Mr. Trump’s principles,” Gruber wrote. “If we say that insurers have to pay for breast-cancer treatment for their insured but allow them to set unaffordable prices or deny insurance altogether, how does that solve the problem?”

For more on why Gruber thinks any ACA replacement plan will come with serious financial risk, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.